On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2

  1. Carolina Corrêa Giron
  2. Aatto Laaksonen
  3. Fernando L. Barroso da Silva

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.virusres.2020.198021
  2. ScreenIT

    SciScore for 10.1101/2020.04.05.026377: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    NIH rigor criteria are not applicable to paper type.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    The “UCSF Chimera 1.11.2” package45 was employed for all molecular visualizations and representations too.
    Chimera
    suggested: (Chimera, RRID:SCR_002959)
    The pairwise sequence alignments were generated by the server EMBOSS Needle68 with default settings.
    EMBOSS
    suggested: (EMBOSS, RRID:SCR_008493)

    Results from OddPub: Thank you for sharing your data.

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    We are careful with the use of stronger statements here due to the limitation of the theoretical approach. Several additional issues remain to be further investigated. Finally, we compared the EE predictions for CR3022’ (34 aa) with CR3022 (33 aa) interacting with SARS-CoV-2 S RBD protein − see Figure 10. The predicted EEs for the interaction with CR3022’ are essentially the same ones observed for CR3022 (27 common aa). This implies that the suggested mutations here do not affected the antigenic regions. Another particularly interesting feature of this computer-designed molecule is that the number of EEs shared with ACE2 has increased from 18 (for CR3022) to 27 (for CR3022’). This might amplify the potential of this mAb candidate to better block the virus-host cell interaction.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • No conflict of interest statement was detected. If there are no conflicts, we encourage authors to explicit state so.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.04.05.026377v1 on bioRxiv